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Abstract
Purpose Cushing’s disease (CD) and acromegaly are
characterized by excessive hormone secretion resulting in
comorbidities such as impaired glucose metabolism, diabetes and hypertension. Pasireotide is a new-generation,
multireceptor-targeted somatostatin receptor ligand
approved for CD (subcutaneous [SC] injection formulation) and acromegaly (long-acting release [LAR] formulation). In clinical studies of pasireotide, hyperglycemiarelated adverse events (AEs) were frequently observed.
This review highlights differences in reported rates of
hyperglycemia in pasireotide trials and discusses risk factors for and management of pasireotide-associated
hyperglycemia.
Methods Clinical trials evaluating pasireotide in patients
with CD or acromegaly were reviewed.
Results The frequency of hyperglycemia-related AEs was
lower in patients with acromegaly treated with pasireotide
LAR (57.3–67.0 %) than in patients with CD treated with
pasireotide SC (68.4–73.0 %). Fewer patients with acromegaly treated with pasireotide LAR discontinued therapy
because of hyperglycemia-related AEs (Colao et al. in J
Clin Endocrinol Metab 99(3):791–799, 2014, 3.4 %;
Gadelha et al. in Lancet Diabetes Endocrinol
2(11):875–884, 2014, 4.0 %) than did patients with CD
treated with pasireotide SC (Boscaro et al. in Pituitary
17(4):320–326, 2014, 5.3 %; Colao et al. in N Engl J Med
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366(10):914–924, 2012, 6.0 %). Hyperglycemia-related
AEs occurred in 40.0 % of patients with acromegaly
treated with pasireotide SC, and 10.0 % discontinued
treatment because of hyperglycemia. Ongoing studies
evaluating pasireotide LAR in patients with CD and management of pasireotide-induced hyperglycemia in patients
with CD or acromegaly (ClinicalTrials.gov identifiers
NCT01374906 and NCT02060383, respectively) will
address these key safety issues.
Conclusions Disease pathophysiology, drug formulation,
and physician experience potentially influence the differences in reported rates of pasireotide-induced hyperglycemia in CD and acromegaly. Hyperglycemic effects
associated with pasireotide have a predictable pattern, can
be managed with antidiabetic agents, and are reversible
upon discontinuation.
Keywords Acromegaly  Cushing’s disease 
Hyperglycemia  Pasireotide

Introduction
Cushing’s disease (CD) and acromegaly are rare diseases
characterized by the increased production of adrenocorticotropic hormone (ACTH) in the former and growth hormone (GH) in the latter [1]. In CD, hypercortisolemia is
caused by the secretion of ACTH from a corticotroph
pituitary tumor. In acromegaly, GH excess, most commonly from a somatotroph pituitary tumor, causes downstream hypersecretion of insulin-like growth factor 1 (IGF1). Chronic elevation of cortisol (CD) and GH and IGF-1
(acromegaly) levels is associated with increased mortality
risk and worsening comorbidities in both conditions [1, 2].
Thus, in both diseases, the treatment goals include
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normalization of hormone levels, reversal of clinical features, prevention of disease recurrence, and reduction in
tumor volume in cases of pituitary macroadenomas [1, 3].
Surgery is considered first-line treatment and provides
adequate control of cortisol levels in many patients with
CD (65–90 %) [4] and GH and IGF-1 levels in patients
with acromegaly (microadenomas, [85 %; macroadenomas, 40–50 %) [3]. Despite the success rates associated
with surgery, 5–10 % of patients with CD [4] and 2–8 % of
patients with acromegaly [3] will experience disease
recurrence within 5 years after achieving postoperative
hormone remission. Medical therapy (sometimes used as a
bridge until adjuvant radiation therapy has taken full effect)
is an option for patients with recurrent or persistent CD or
acromegaly following surgery.
Pasireotide is a new-generation, multireceptor-targeted
somatostatin receptor ligand (SRL) approved for the
treatment of patients with CD (subcutaneous [SC] formulation) [5] or acromegaly (long-acting release [LAR] formulation) [6]. It is indicated for patients who do not
achieve control with surgery and/or for whom surgery is
not an option [5, 6]. Pasireotide binds to several known
somatostatin receptor (sst) subtypes that are expressed by
corticotroph and somatotroph tumors, resulting in
decreased secretion of ACTH and GH, respectively. Both
corticotroph and somatotroph tumors express relatively
high levels of sst2 and sst5 [7]. Compared with octreotide,
pasireotide binds with higher affinity to sst1 (30-fold), sst3
(5-fold), and sst5 (39-fold) and lower affinity to sst2 (3fold) [8, 9]. Pasireotide also binds with higher affinity than
lanreotide to sst1 (19-fold), sst3 (9-fold), and sst5 (106-fold)
but with lower affinity to sst2 (2-fold) [8]. The combination
of the broad binding profile of pasireotide with its preferential binding to sst5 provides therapeutic rationale for its
use in the treatment of CD and acromegaly. Although its
efficacy in clinical studies has warranted consideration of
pasireotide as the first treatment of choice among SRLs, the
effect of pasireotide on glucose metabolism should be
considered when choosing the best SRL option for each
patient [10]. This review provides a summary of data from
clinical studies and case reports that document hyperglycemia-related adverse events (AEs) associated with
pasireotide in patients with either acromegaly or CD.

Clinical efficacy of pasireotide in CD
and acromegaly
Pasireotide SC in CD
In a phase 3 study of 162 patients with persistent or
recurrent CD or newly diagnosed disease, who were not
eligible for surgery, twice-daily injections of pasireotide
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SC provided rapid reductions in mean levels of urinary-free
cortisol (UFC) that were sustained during treatment [11].
After 12 months of pasireotide 600 and 900 lg twice daily,
13 and 25 % of patients achieved UFC levels at or below
the upper limit of the normal range, respectively. At
12 months, tumor volume reductions were also observed
with 600 lg (-9.1 %) and 900 lg (-43.8 %). Decreases
in mean UFC were associated with improved signs and
symptoms of disease, including systolic blood pressure
(mean change from baseline, -6.1 mm Hg), diastolic
blood pressure (mean change from baseline, -3.7 mm Hg),
weight (mean change from baseline, -6.7 kg), and healthrelated quality-of-life score (mean change from baseline,
11.1 points). Improvements in facial rubor and supraclavicular and dorsal fat pads were also reported. In addition,
69 % of patients (n = 11) who remained in the study for
60 months achieved UFC levels at or below the upper limit
of the normal range [12].
Pasireotide in acromegaly
In a phase 3 study of patients with acromegaly who were
naive to medical therapy, significantly more patients
achieved biochemical control (GH \ 2.5 ng/mL and ageand sex-adjusted IGF-1) after 1 year of monthly injections
of pasireotide LAR 40 mg than after 1 year of monthly
injections of octreotide LAR 20 mg (31.3 vs 19.2 %) [13].
Tumor volume reductions were similar between the 2
treatment groups (pasireotide LAR, 40 %; octreotide LAR,
38 %), and both therapies improved symptoms of disease
(e.g., perspiration, fatigue, osteoarthralgia, paresthesia,
headache) and quality of life.
In another phase 3 study that enrolled patients with
acromegaly who were inadequately controlled by other
SRLs, monthly injections of pasireotide LAR 40 mg
(15 %) and 60 mg (20 %) provided greater biochemical
control than the active control treatment (octreotide LAR
30 mg or lanreotide Autogel 120 mg; 0 %) at 6 months
[14]. Furthermore, more patients in the pasireotide LAR 40
and 60-mg groups achieved tumor volume reductions of
[25 % than did those in the active control group (18.5 and
10.8% vs 1.5 %). Improvements in symptom severity
scores also occurred at higher degrees in patients in the
pasireotide LAR 40 and 60-mg groups than in those in the
active control group. Symptoms included headache, fatigue, perspiration, paresthesia, and osteoarthralgia.
The efficacy and safety of pasireotide SC in acromegaly
have also been investigated. In a phase 2 extension study,
33 % of patients (3 of 9) achieved biochemical control
after 24 months of treatment [15]. Up to 75 % of patients
who responded to treatment demonstrated tumor volume
reductions of C20 %. Additionally, the number of patients
showing improvements in symptoms of disease (i.e.,
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headache, fatigue, perspiration, osteoarthralgia) approximately doubled during the course of the study.

Hyperglycemia associated with pasireotide in CD
and acromegaly
Clinical trials experience
In clinical trials, the safety profile of pasireotide included
AEs, mostly related to gastrointestinal symptoms and
cholelithiasis, that were largely consistent with other SRLs
[5, 6]. However, compared with other SRLs, treatment with
pasireotide is associated with a higher frequency of hyperglycemia in patients with CD or acromegaly [11, 13, 14]. The
reported rates of hyperglycemia-related AEs and the percentage of patients who discontinued therapy from such
events differ across clinical studies of pasireotide in CD and
acromegaly (Table 1). Further comparison of the rates shows
that the frequency of hyperglycemia-related AEs was lower
in patients with acromegaly who received pasireotide LAR
(57.3–67.0 %) [13, 14] than in patients with CD who
received pasireotide SC (68.4–73.0 %) [11, 16]. Interestingly, fewer patients with acromegaly who received pasireotide LAR discontinued treatment because of
hyperglycemia-related AEs, as reported in 2 separate trials
(3.4 and 4.0 %), [13, 14] compared with patients with CD
who received pasireotide SC, also as reported in 2 separate
trials (6.0 and 5.3 %) [11, 16]. In a clinical study that evaluated the efficacy and safety of pasireotide SC in acromegaly, hyperglycemia-related AEs occurred in 40.0 % of
patients, and 10.0 % of patients discontinued treatment
because of such events [15].

Several underlying factors could contribute to differences in the reported frequency of pasireotide-induced
hyperglycemia among patients with CD or acromegaly. In
clinical studies of acromegaly, the rates of pasireotide-induced hyperglycemia-related AEs were lower than those in
CD (Fig. 1a). This could be related to disease pathophysiology since the dysregulation of glucose metabolism in
CD and acromegaly could be uniquely linked to downstream effects associated with chronic exposure to elevated
levels of cortisol or GH/IGF-1, respectively [17, 18]. Also,
because studies of pasireotide in CD occurred before those
in acromegaly, the benefit of physician experience could
have led to lower rates of study discontinuation in the
acromegaly trials (Fig. 1b). This could be attributed to a
better understanding of the mechanisms underlying pasireotide-induced hyperglycemia and its optimal management
in patients with acromegaly or CD. Despite the higher
frequency of hyperglycemia-related AEs associated with
pasireotide than with other medical therapies for acromegaly or CD, results from other clinical studies suggest that
the hyperglycemic effect associated with treatment has a
predictable pattern, can be managed with antidiabetic
medications (ADM), and is reversible upon discontinuation
of treatment with pasireotide.
Mechanisms of pasireotide-induced hyperglycemia
It has been reported that impaired glucose metabolism
observed in patients with CD or acromegaly is uniquely
associated with disease pathophysiology. Chronic exposure
to elevated GH and IGF-1 levels is associated with insulin
resistance, which may be counteracted by the compensatory hyperfunction of pancreatic beta cells in patients

Table 1 Hyperglycemia-related AEs associated with pasireotide in clinical studies of Cushing’s disease or acromegaly
Study

Disease

Study
description

Study
duration

Drug formulation (dosing)

Hyperglycemiarelated AEs

Colao
et al.
[11]

Cushing’s
disease

Phase 3

12 months

Pasireotide SC (600, 900 lg b.i.d)

73.0 %

6.0

Boscaro
et al.
[16]

Cushing’s
disease

Phase 2,
extension

6 months

Pasireotide SC (600 lg b.i.d; 900 lg
with suboptimal control)

68.4 %

5.3

Colao
et al.
[13]

Acromegaly

Phase 3

12 months

Pasireotide LAR (40 mg; dose increase
to 60 mg with suboptimal control)

57.3 %

3.4

Gadelha
et al.
[14]

Acromegaly

Phase 3

6 months
or
longer

Pasireotide LAR (40, 60 mg)

40 mg, 67.0 %

4.0

Petersenn
et al.
[15]

Acromegaly

6 months
or
longer

Pasireotide SC (200, 400, 600 lg;
900 lg with suboptimal control)

Phase 2,
extension

60 mg, 61.0 %

AE adverse event, b.i.d twice daily, LAR long-acting release, SC subcutaneous
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Discontinuations due to
hyperglycemia-related AEs
(%)

40.0 %

10.0
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Percentage of patients with
hyperglycemia-related AEs

a
Acromegaly
80
60

CD
73%

67%

68%

61%

57%

40
20
0
Colao
2014 [13]

40 mg

60 mg

Gadelha
2014 [14]

Colao
Boscaro
2012 [11] 2014 [16]

Percentage of patients who
discontinued because of
hyperglycemia-related AEs

b
Acromegaly
7
6
5
4
3
2
1
0

CD
6%

3.4%

Colao
2014 [13]

5.3%

Levels of fasting plasma glucose and glycated
hemoglobin during treatment course

3.8%

Gadelha
2014 [14]

two mechanisms could explain why the hyperglycemic
effect is transient. First, pasireotide has minimal effects on
glucagon secretion and no effects on insulin sensitivity in
healthy volunteers [19]. In contrast, octreotide and lanreotide suppress glucagon secretion, which could be due to
increased binding of sst2 [21, 22], a key mediator of glucagon secretion to which octreotide and lanreotide bind
with greater affinities than pasireotide [8]. By improving
biochemical control, it is likely that insulin sensitivity will
increase, which should improve glucose tolerance, even if
insulin secretion remains reduced. Second, it was reported
that levels of IGF-binding protein 2 increased after
24 weeks of pasireotide LAR [24], which could attenuate
the long-term hyperglycemic effects of pasireotide LAR.

Colao
2012 [11]

Boscaro
2014 [16]

Fig. 1 Factors potentially affecting reported differences in a the
frequency of pasireotide-induced hyperglycemia and b the frequency
of discontinuations associated with hyperglycemia among patients
with CD or acromegaly. AE adverse event, CD Cushing’s disease,
LAR long-acting release, SC subcutaneous. Figure was created with
Adobe Illustrator CC 2015

with acromegaly with normal glucose tolerance [18].
Similarly, in CD, chronic hypercortisolism blocks the
binding of insulin to peripheral tissues, resulting in insulin
resistance, and inhibits the release of insulin by pancreatic
beta cells [17]. Excess cortisol can also affect glucose
metabolism in hepatic tissue by stimulating gluconeogenesis or indirectly inhibiting insulin sensitivity by depleting
storage of hepatic glycogen.
Recently, there has been a greater understanding of the
mechanisms that underlie the development of hyperglycemia in patients with acromegaly or CD treated with
pasireotide. The hyperglycemic effects of pasireotide are
primarily due to its tendency to reduce insulin and incretin
secretion [19]. Insulin secretion is mediated in large part by
sst2 and sst5 [20, 21], and glucagon secretion is mediated
primarily by sst2 [21, 22]. Pasireotide binds to sst2 and sst5
and binds with highest affinity to sst5, which is expressed
not only by pituitary cells but also by other cell types. For
example, pasireotide binds to sst5 in pancreatic islet cells,
which leads to reduced insulin secretion that is not
observed with SRLs that bind to sst2 with greater affinity
[19, 23]. Reduced insulin levels associated with pasireotide
are unable to counterbalance the reduced insulin sensitivity
caused by uncontrolled acromegaly or CD [18]. However,

Fasting plasma glucose (FPG) and glycated hemoglobin
(HbA1c) levels are parameters used to assess glycemic
control [25]. In a clinical study of patients with acromegaly, it was reported that up to 45 % of patients with
baseline FPG between 100 and 126 mg/dL had FPG levels
C126 mg/dL after 26 months of pasireotide LAR [26]. In a
clinical study of patients with CD treated with pasireotide,
worsened diabetic status was observed in 76 % of patients
who had normal HbA1c levels at baseline [27]. During the
course of treatment in patients with acromegaly or CD,
mean FPG levels peaked after 1 month of pasireotide and
thereafter remained stable or slightly decreased
[11, 12, 14, 26–28]. In some patients, levels of FPG and
HbA1c were stabilized during the course of treatment with
pasireotide LAR for up to 26 months [26, 27]. These
observations suggest that pasireotide initially induces an
increase in FPG and HbA1c levels, which then stabilize
during the course of treatment.
Predictive risk factors of pasireotide-induced
hyperglycemia
In CD, the prevalence of impaired glucose tolerance or
diabetes mellitus at diagnosis is 21–64 % and 20–47 %,
respectively [29]. Similarly, the prevalence of impaired
fasting glucose and diabetes are higher in patients with
acromegaly compared with the general population, predisposing patients to a greater risk of developing hyperglycemia [30]. This suggests that baseline glycemic status
before the initiation of pasireotide treatment could be
predictive of the extent and severity of hyperglycemia
associated with treatment. In a phase 3 study of patients
with acromegaly, baseline FPG [ 100 mg/dL correlated
with the development of higher FPG and HbA1c levels and
a higher degree of hyperglycemia during pasireotide LAR
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treatment [24]. Moreover, it was reported that increasing
the dose of pasireotide LAR from 40 to 60 mg was associated with a 21–36 % increased risk of developing
hyperglycemia [31, 32]. Regarding disease control as a
predictive factor, reductions in GH and IGF-1 in patients
with newly diagnosed acromegaly who were treated with
octreotide for 6 months without ADM were shown to
correlate with change in HbA1c levels [33]; however, a
similar association in patients treated with pasireotide has
not yet been studied. Other predictive risk factors associated with developing hyperglycemia in patients with
acromegaly treated with pasireotide LAR include body
mass index C25 kg/m2, diabetes at baseline, and history of
dyslipidemia [34]. Because certain populations are at
greater risk of hyperglycemia associated with pasireotide,
proactive management and monitoring of these patients are
critical for improving clinical outcomes.

Management of pasireotide-induced
hyperglycemia
Optimal treatment with ADMs
As previously discussed, in phase 3 studies of pasireotide
SC in CD and pasireotide LAR in acromegaly, the majority
of hyperglycemia-related AEs were mild to moderate in
severity [11, 13, 14]. Even in patients with acromegaly
with FPG [ 250 mg/dL at baseline, ADM initiated within
2 weeks of the first dose of pasireotide LAR led to rapid
decreases in FPG, suggesting that early treatment intervention with ADMs could optimally manage pasireotideinduced hyperglycemia [34]. Metformin has been shown to
be minimally effective in reducing pasireotide-induced
hyperglycemia in healthy volunteers [35]; however, this
study measured effects on glucose metabolism after only
6 days, which may have been too brief to observe longterm effects of metformin. For instance, metformin has
been shown to increase glucagon-like peptide 1 (GLP-1)
[36], which may at least partially compensate for the
reduction in GLP-1 associated with pasireotide [19].
Antidiabetic medication, primarily metformin, was
administered in 38–48 % of patients in acromegaly trials
[13, 14, 26]. Mean HbA1c levels in patients with acromegaly naive to medical therapy who developed pasireotideinduced hyperglycemia were \7 % after 12 months when
treated with metformin alone or in combination with other
ADMs [37]. A case study of a patient with CD exemplified
that control of hyperglycemia could be achieved with
metformin in combination with glipizide and sitagliptin
[38]. These results suggest that metformin is useful for
some patients in treating pasireotide-associated
hyperglycemia.
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In some case study reports, treatment with metformin
alone was insufficient in providing glycemic control to
patients with pasireotide-induced hyperglycemia [39–41].
In these cases, treatment with insulin alone or glipizide
with or without insulin was able to quickly reduce FPG
levels. Dietary control or modification could also be
important for management of pasireotide-induced hyperglycemia [16, 42]. In healthy volunteers who were
administered pasireotide SC, coadministration with
liraglutide, a GLP-1 agonist, was most effective in reducing serum glucose levels (72 % lower than with pasireotide
alone) [35]. Coadministration with vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was most effective in
attenuating the reduction in serum insulin levels (71 %
higher than with pasireotide alone). These studies indicate
that by following standard guidelines for the treatment of
diabetes and adapting treatment with ADMs on the basis of
each patient’s glycemic status, pasireotide-induced hyperglycemia can be effectively managed.
Treatment recommendations
Medical expert recommendations have been established for
the management of pasireotide-induced hyperglycemia in
patients with CD [17, 43]. In patients not currently treated
with insulin, and particularly for those with insulin resistance, it is recommended that metformin be initiated or
continued if FPG [ 126 g/dL or HbA1c is [6.5 % [43]. In
cases in which patients fail to achieve glycemic control
with metformin, it is suggested that a DPP-4 inhibitor be
added. A GLP-1 receptor agonist should replace the DPP-4
inhibitor if HbA1c remains [7.0 %. If neither DPP-4
inhibitors nor GLP-1 receptor agonists provide glucose
control, it is suggested that treatment with insulin be initiated while maintaining metformin treatment. Although no
specific recommendations regarding pasireotide-induced
hyperglycemia in patients with acromegaly have been
published, treatment with metformin plus a DPP-4 inhibitor, GLP-1 agonist, or insulin would most likely have
similar efficacy.
Monitoring recommendations
Patients with CD or acromegaly who initiate, discontinue,
or need dose adjustment of pasireotide should be proactively managed in accordance with current monitoring
guidelines and recommendations. Levels of FPG and
HbA1c should be evaluated before initiation of treatment,
and blood glucose should be monitored weekly for the first
2–3 months after initiation and for the first 2–6 weeks after
a dose increase [5, 6]. Similarly, medical expert opinion
also recommends that, in patients with normal glucose
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metabolism prior to initiating pasireotide, fasting and
postprandial glucose levels should be monitored several
times per day, twice during the first week, and once weekly
thereafter [17, 43]. Moreover, patients with abnormal
glucose metabolism during treatment should be monitored
daily upon initiating pasireotide and while adjusting
treatment as necessary to optimally control glycemic levels
[5, 6, 17, 43]. If warranted, dose reduction or discontinuation of pasireotide should be implemented if hyperglycemia is not controllable despite medical management
[5, 6]. It is suggested that FPG and HbA1c levels of patients
who discontinue pasireotide may need to be assessed frequently to reduce the risk of developing hypoglycemia.

Reversibility of hyperglycemia
upon discontinuation of pasireotide
Clinical studies of pasireotide in healthy volunteers and in
patients with CD or acromegaly suggest that the hyperglycemic effects associated with pasireotide have a predictable pattern and could be effectively managed by
following recommended guidelines set forth by expert
opinions [5, 6, 17, 43]. Moreover, deterioration in glycemic
status associated with pasireotide is reversible upon treatment discontinuation, which potentially restores glycemic
parameters to normoglycemic levels [44]. The reversibility
of the hyperglycemic effects of pasireotide has been shown
in a pharmacokinetic analysis of single-dose administration, in which mean glucose levels increased to C200 lg
and then normalized 23 h after injection [45]. In a previous
case study, normalization of glycemic levels was demonstrated in a patient who discontinued pasireotide SC
because of lack of response to treatment [44]. In a phase 3
clinical trial of patients with acromegaly who were treated
with pasireotide, mean FPG and mean HbA1c levels were
reduced to 104 mg/dL (mean value at baseline, 127 mg/
dL) and to 6.12 % (mean value at baseline, 6.71 %),
respectively, within 3 months of switching from pasireotide LAR to octreotide LAR [28]. In conclusion, hyperglycemia associated with pasireotide is transient and not
expected to cause long-term effects if pasireotide is
discontinued.

Conclusions
Pasireotide is a viable medical therapy option for patients
with CD or acromegaly but is associated with higher rates
of hyperglycemia and diabetes mellitus than other medical
therapies. Further research is needed to determine optimal
treatment strategies with ADMs to achieve glycemic control in patients with pasireotide-induced hyperglycemia.
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For example, a multivariate analysis could be performed of
baseline FPG and HbA1c levels across clinical studies of
pasireotide in CD or acromegaly to further assess the
predictability and manageability of pasireotide-induced
hyperglycemia. A phase 4 study is currently ongoing that
will evaluate the effects of incretin-based therapy compared with insulin on glycemic control at 16 weeks in
patients with CD or acromegaly (ClinicalTrials.gov identifier NCT02060383) [46]. Significant progress has been
made over the years to better understand the mechanisms
by which impaired glucose metabolism in patients is
uniquely linked to the disease pathophysiology of CD and
acromegaly and how pasireotide modulates insulin secretion and sensitivity. There is growing evidence to demonstrate that proactive management with ADMs can
effectively manage hyperglycemia-related AEs associated
with pasireotide during the course of treating patients with
CD or acromegaly.
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